Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised by the EMA for therapeutic use in multiple sclerosis, including chronic progressive forms.
-
EMA approval · 2026-08-20EMA Authorised: Ocrevus (ocrelizumab) — Roche Registration GmbH
EMA has authorised Ocrevus (ocrelizumab) by Roche Registration GmbH for therapeutic use in multiple sclerosis.
-
EMA approval · 2026-08-20EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Authorised status for Kesimpta (ofatumumab) in relapsing-remitting multiple sclerosis in the EU.
-
EMA approval · 2026-08-11EMA Authorised: Tecfidera (dimethyl fumarate) — Biogen Netherlands B.V.
Authorisation of Tecfidera (dimethyl fumarate) in the European Union for the treatment of multiple sclerosis.
-
EMA approval · 2026-08-06EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.
EMA has authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, expanding Biogen's portfolio in this indication…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-30EMA Authorised: Gilenya (fingolimod hydrochloride) — Novartis Europharm Limited
Gilenya (fingolimod hydrochloride) has been authorised for use in the European Union for multiple sclerosis.
-
EMA approval · 2026-07-22EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited
Dimethyl fumarate Mylan has been authorised for use in the European Union as a treatment for multiple sclerosis.
-
EMA approval · 2026-07-06EMA Authorised: Tysabri (natalizumab) — Biogen Netherlands B.V.
European Medicines Agency authorises Tysabri (natalizumab) for multiple sclerosis.
-
EMA approval · 2026-07-03EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Kesimpta (ofatumumab) has been authorised in the EU for Relapsing-Remitting Multiple Sclerosis.
-
EMA approval · 2026-06-25EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised in the EU for multiple sclerosis, including chronic progressive forms.
-
EMA approval · 2026-06-12EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited
Dimethyl fumarate by Mylan Pharmaceuticals Limited has been authorised for multiple sclerosis in the EU.
-
EMA approval · 2026-06-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
FDA approval · 2026-04-20FDA Approved: DALFAMPRIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for dalfampridine (generic). The approval enables the marketing of a generic …
-
EMA approval · 2026-04-16EMA Authorised: Ocrevus (ocrelizumab) — Roche Registration GmbH
The European Medicines Agency authorised Ocrevus (ocrelizumab) for treating multiple sclerosis, with Roche Registration GmbH as the marketin…
-
EMA approval · 2026-04-08EMA Authorised: Rebif (interferon beta-1a) — Merck Europe B.V.
EMA has authorised Rebif (interferon beta-1a) for use in the treatment of multiple sclerosis, with Merck Europe B.V. listed as the marketing…
-
FDA approval · 2026-04-01FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kesimpta (ofatumumab) by Novartis Pharmaceuticals Corporation. This approval indicates an up…
-
EMA approval · 2026-03-17EMA Authorised: Plegridy (peginterferon beta-1a) — Biogen Netherlands B.V.
The EMA authorised Plegridy (peginterferon beta-1a) from Biogen Netherlands B.V. for the treatment of multiple sclerosis.
-
FDA approval · 2026-03-12FDA Approved: FINGOLIMOD — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for Fingolimod from Quallent Pharmaceuticals Health LLC under an ANDA, updating the approved fingoli…
-
EMA approval · 2026-03-06EMA Authorised: Tyruko (natalizumab) — Sandoz GmbH
The European Medicines Agency authorised Tyruko, a natalizumab biosimilar by Sandoz GmbH, for treatment of multiple sclerosis including the …
-
EMA approval · 2026-03-03EMA Authorised: Zeposia (ozanimod hydrochloride) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Zeposia (ozanimod hydrochloride) for relapsing-remitting multiple sclerosis and ulcerative colitis; the marketing aut…
-
EMA approval · 2026-03-02EMA Authorised: Fingolimod Accord (fingolimod hydrochloride) — Accord Healthcare S.L.U.
The EMA authorised Fingolimod Accord (fingolimod hydrochloride) from Accord Healthcare S.L.U. for relapsing-remitting multiple sclerosis.
-
FDA approval · 2026-02-24FDA Approved: FINGOLIMOD — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Fingolimod from Aurobindo Pharma Limited, authorizing a generic version of the MS therapy Fingol…
-
FDA approval · 2026-02-12FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for GLATOPA (glatiramer acetate), a generic injectable for multiple sclerosis.
-
FDA approval · 2026-02-12FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved GLATOPA, a generic glatiramer acetate product by Sandoz, via a supplemental application to an approved ANDA for use in multiple…
-
FDA approval · 2026-02-11FDA Approved: GLATIRAMER ACETATE — Original Application (AJENAT PHARMACEUTICALS LLC)
FDA approved a generic version of glatiramer acetate (AJENAT Pharmaceuticals LLC) under an original ANDA for the treatment of multiple scler…